BioLineRx Ltd. (BLRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7699 |
| Open | 0.7800 |
| Bid | 0.7810 x 800 |
| Ask | 0.8300 x 800 |
| Day's Range | 0.7700 - 0.7999 |
| 52 Week Range | 0.5500 - 1.9800 |
| Volume | |
| Avg. Volume | 275,175 |
| Market Cap | 49.656M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7850 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.67 |
- Insider Monkey
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications BioLineRx. Please go ahead. John Lacey: Thank […]
- Zacks Small Cap Research
BLRX: Confidence in a Strong Launch
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November
- PR Newswire
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its audited 2022 annual financial results for the year ended December 31, 2022, and provided recent corporate and portfolio updates.
